Report cover image

Peptic Ulcer Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Dec 01, 2024
Length 160 Pages
SKU # FOB19410867

Description

Peptic Ulcer Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Peptic Ulcer Drugs Market

The peptic ulcer drugs market size was valued at USD 4.25 billion in 2019, and the market is now projected to grow from USD 4.25 billion in 2019 to USD 5.13 billion by 2027, exhibiting a CAGR of 2.4% during the forecast period of 2019-2027.

Pharmaceutical like AstraZeneca is experiencing boom regardless of the pandemic. They have stepped forward delivery chain, R&D abilities and production control. Government regulations have relaxed, allowing physicians to offer telemedicine care. As a result, sales growth is anticipated to hold regardless of the COVID-19.

Approved steroidal anti-inflammatory drugs offer faster and less expensive healthcare access, increasing their popularity. Pharmaceutical companies are investing in growing OTC variations of peptic ulcer drugs, that is expected to power peptic ulcer drugs market growth within the future.

Peptic ulcers affect 10% of the arena's populace, with four million people struggling yearly within the U.S. The main purpose is H. Pylori bacterium infection and elevated NSAID consumption. The disease is on the whole affecting older individuals, with high occurrence between 55 and 65 years old. The developing geriatric populace is contributing to the worldwide marketplace enlargement, highlighting the need for effective treatments and prevention techniques.

Comprehensive Analysis of Peptic Ulcer Drugs Market

The marketplace is divided into antibiotics, proton pump inhibitors, and gastric ulcers. Antibiotics held the dominant market share due to excessive adoption rate and triple therapy treatment for Helicobacter pylori infection. Proton pump inhibitors are anticipated to develop drastically with the very best CAGR. The marketplace is segmented into gastric and duodenal ulcers, with duodenal ulcers main because of the growing incidence and consciousness of treatment options. Distribution channels consist of clinic pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are expected to have the largest marketplace proportion due to improved affected person visits and the ease of availability. The growing recognition of online pharmacies is anticipated to in addition increase the segment's growth.

The North America region lead the peptic ulcer drugs market share by benefitting a market size of USD 1.76 billion in 2019 due to developing prevalence of peptic ulcers, with approximately 4 million human beings struggling every year.

Key organizations includes AstraZeneca, Novartis AG GlaxoSmithKline %, Takeda Pharmaceutical Company Limited, Mylan Pharmaceuticals Inc., Abbott and Zydus Cadila.

Famotidine to cope with belly ulcers is below research at Northwell Health in New York City as a remedy for the covid-19.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2016-2027

Base Year 2019

Forecast Period 2020-2027

Historical Period 2016-2018

Unit Value (USD billion)

SegmentationDrug Type; Ulcer Type; End User and Geography

By Drug Type

Proton Pump Inhibitors

H2 Antagonists

Antibiotics

Others

By Ulcer Type

Gastric Ulcer

Duodenal Ulcer

By End User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Geography

North America (USA, Canada)

• Europe (UK, Germany, France, Italy, Spain, Scandinavia, Rest of Europe)

• Asia Pacific (Japan, China, India, Australia, Southeast Asia,Rest of Asia Pacific)

• Latin America (Brazil, Mexico, Rest of Latin America)

• Middle East and Africa (GCC, South Africa,Rest of MEA)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

160 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Peptic Ulcer, By Country/Region
4.2. Pipeline Analysis, By Key Players
4.3. Recent Industry Developments
4.4. Regulatory Scenario-by Key Countries
4.5. Impact of COVID-19 on Peptic Ulcer Drugs Market
5. Global Peptic Ulcer Drugs Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Type
5.2.1. Proton Pump Inhibitor
5.2.2. H2 Antagonists
5.2.3. Antibiotics
5.2.4. Others
5.3. Market Analysis, Insights and Forecast – By Ulcer Type
5.3.1. Gastric Ulcer
5.3.2. Duodenal Ulcer
5.4. Market Analysis, Insights and Forecast – By End User
5.4.1. Hospital Pharmacies
5.4.2. Retail Pharmacies
5.4.3. Online Pharmacies
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
6. North America Peptic Ulcer Drugs Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Type
6.2.1. Proton Pump Inhibitor
6.2.2. H2 Antagonists
6.2.3. Antibiotics
6.2.4. Others
6.3. Market Analysis – By Ulcer Type
6.3.1. Gastric Ulcer
6.3.2. Duodenal Ulcer
6.4. Market Analysis – By End User
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies
6.4.3. Online Pharmacies
6.5. Market Analysis – By Country
6.5.1. U.S.
6.5.2. Canada
7. Europe Peptic Ulcer Drugs Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis – By Drug Type
7.2.1. Proton Pump Inhibitor
7.2.2. H2 Antagonists
7.2.3. Antibiotics
7.2.4. Others
7.3. Market Analysis – By Ulcer Type
7.3.1. Gastric Ulcer
7.3.2. Duodenal Ulcer
7.4. Market Analysis – By End User
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Online Pharmacies
7.5. Market Analysis – By Country/Sub-region
7.5.1. U.K.
7.5.2. Germany
7.5.3. France
7.5.4. Spain
7.5.5. Italy
7.5.6. Scandinavia
7.5.7. Rest of Europe
8. Asia Pacific Peptic Ulcer Drugs Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis – By Drug Type
8.2.1. Proton Pump Inhibitor
8.2.2. H2 Antagonists
8.2.3. Antibiotics
8.2.4. Others
8.3. Market Analysis – By Ulcer Type
8.3.1. Gastric Ulcer
8.3.2. Duodenal Ulcer
8.4. Market Analysis – By End User
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
8.5. Market Analysis – By Country/Sub-region
8.5.1. Japan
8.5.2. China
8.5.3. India
8.5.4. Australia
8.5.5. Southeast Asia
8.5.6. Rest of Asia Pacific
9. Latin America Peptic Ulcer Drugs Market Analysis, Insights and Forecast, 2016-2027
9.1. Key Findings / Summary
9.2. Market Analysis – By Drug Type
9.2.1. Proton Pump Inhibitor
9.2.2. H2 Antagonists
9.2.3. Antibiotics
9.2.4. Others
9.3. Market Analysis – By Ulcer Type
9.3.1. Gastric Ulcer
9.3.2. Duodenal Ulcer
9.4. Market Analysis – By End User
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Market Analysis – By Country/Sub-region
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East & Africa Peptic Ulcer Drugs Market Analysis, Insights and Forecast, 2016-2027
10.1. Key Findings / Summary
10.2. Market Analysis – By Drug Type
10.2.1. Proton Pump Inhibitor
10.2.2. H2 Antagonists
10.2.3. Antibiotics
10.2.4. Others
10.3. Market Analysis – By Ulcer Type
10.3.1. Gastric Ulcer
10.3.2. Duodenal Ulcer
10.4. Market Analysis – By End User
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Analysis – By Country/Sub-region
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2019)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (based on availability))
11.5.1. AstraZeneca
11.5.1.1. Overview,
11.5.1.2. Products & Services,
11.5.1.3. SWOT Analysis,
11.5.1.4. Recent Developments,
11.5.1.5. Strategies,
11.5.1.6. Financials (based on availability)
11.5.2. Novartis AG
11.5.2.1. Overview,
11.5.2.2. Products & Services,
11.5.2.3. SWOT Analysis,
11.5.2.4. Recent Developments,
11.5.2.5. Strategies,
11.5.2.6. Financials (based on availability)
11.5.3. Pfizer Inc.
11.5.3.1. Overview,
11.5.3.2. Products & Services,
11.5.3.3. SWOT Analysis,
11.5.3.4. Recent Developments,
11.5.3.5. Strategies,
11.5.3.6. Financials (based on availability)
11.5.4. GlaxoSmithKline plc.
11.5.4.1. Overview,
11.5.4.2. Products & Services,
11.5.4.3. SWOT Analysis,
11.5.4.4. Recent Developments,
11.5.4.5. Strategies,
11.5.4.6. Financials (based on availability)
11.5.5. Takeda Pharmaceutical Company Limited.
11.5.5.1. Overview,
11.5.5.2. Products & Services,
11.5.5.3. SWOT Analysis,
11.5.5.4. Recent Developments,
11.5.5.5. Strategies,
11.5.5.6. Financials (based on availability)
11.5.6. Mylan Pharmaceuticals Inc.
11.5.6.1. Overview,
11.5.6.2. Products & Services,
11.5.6.3. SWOT Analysis,
11.5.6.4. Recent Developments,
11.5.6.5. Strategies,
11.5.6.6. Financials (based on availability)
11.5.7. Abbott
11.5.7.1. Overview,
11.5.7.2. Products & Services,
11.5.7.3. SWOT Analysis,
11.5.7.4. Recent Developments,
11.5.7.5. Strategies,
11.5.7.6. Financials (based on availability)
11.5.8. Zydus Cadila
11.5.8.1. Overview,
11.5.8.2. Products & Services,
11.5.8.3. SWOT Analysis,
11.5.8.4. Recent Developments,
11.5.8.5. Strategies,
11.5.8.6. Financials (based on availability)
11.5.9. Other Players
11.5.9.1. Overview,
11.5.9.2. Products & Services,
11.5.9.3. SWOT Analysis,
11.5.9.4. Recent Developments,
11.5.9.5. Strategies,
11.5.9.6. Financials (based on availability)
12. Strategic Recommendations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us